Long acting GLP-1 receptor agonist (injectable)
Albiglutide 50 mg subcutaneous once weekly
ALBI_SC_50MG_QW
Withdrawn from the market in 2018 for commercial reasons.
Related
- All doses pooled: Albiglutide injection
- Albiglutide 100 mg injection every 4 weeks
- Albiglutide 4 mg injection once weekly
- Albiglutide 15 mg injection once weekly
- Albiglutide 30 mg subcutaneous once weekly
- Albiglutide 15 mg injection every 2 weeks
- Albiglutide 30 mg injection every 2 weeks
- Albiglutide 50 mg injection every 2 weeks
- Albiglutide 50 mg injection every 4 weeks
- Albiglutide flexible dose injection once weekly
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.47 (-2.00 to -0.63) | 0.70 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -1.35 (-2.30 to 0.39) | 0.70 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -1.01 (-1.93 to 0.09) | 0.36 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 0.85 (-2.91 to 5.34) | 0.31 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD 1.72 (-3.88 to 7.36) | 0.32 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -0.19 (-5.33 to 4.61) | 0.20 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 14.70 (3.10 to 57.09) | 0.79 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Placebo | OR 2.31 (0.57 to 7.42) | 0.31 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Placebo | OR 4.00 (0.49 to 17.14) | 0.49 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.50 (0.04 to 4.76) | 0.46 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 5.45 (2.00 to 15.27) | 0.22 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.61 (0.74 to 3.41) | 0.44 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.23 (0.27 to 5.00) | 0.43 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.21 (0.74 to 1.94) | 0.38 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.84 (0.64 to 5.66) | 0.45 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.50 (0.80 to 2.76) | 0.69 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.57 (0.54 to 11.23) | 0.50 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.15 (0.69 to 1.91) | 0.65 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.38 (1.07 to 5.53) | 0.35 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 1.09 (0.09 to 12.19) | 0.42 |
Trials
- NCT02229227Study 200977: Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine in the Treatment of Subjects With Type 2 Diabetes Mellitus: The Switch Study2014 · 814 randomized · 26 weeks
- NCT01733758A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Monotherapy Study to Determine the Efficacy and Safety of 2 Dose Levels of Albiglutide in Subjects With Type 2 Diabetes Mellitus2013 · 494 randomized · 52 weeks
- NCT00849017A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Two Dose Levels of Albiglutide Compared With Placebo in Subjects With Type 2 Diabetes Mellitus2009 · 309 randomized · 156 weeks